Covid-19 - Le miracle vaccinal doit inclure rigueur et prudence (notice n° 977558)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04265cam a2200265 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250125123733.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Agut, Henri |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Covid-19 - Le miracle vaccinal doit inclure rigueur et prudence |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2021.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 71 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | RésuméEn dehors des vaccins anti-SARS-CoV-2, il y a peu de perspectives positives concernant la maîtrise de l’épidémie de Covid-19. De façon schématique, deux stratégies antagonistes et extrêmes ont été proposées, le zéro-Covid et l’immunité de groupe. Entre les deux, des mesures souvent oscillantes, fondées sur des considérations médicales mais aussi sociétales et politiques, ont été prises sans effet majeur sur l’évolution de l’épidémie. Les vaccins changent la donne en offrant une opportunité réelle de protéger de façon durable toute la population contre l’infection et d’éliminer la circulation du virus. Les vaccins Pfizer, Moderna et AstraZeneca, les trois actuellement autorisés en France, induisent globalement des taux de protection remarquables de 95 %, 94 % et 70 % respectivement. La surprise a été que cette efficacité soit obtenue après un développement rapide, en ciblant seulement comme antigène la protéine virale S, et en utilisant l’administration de vecteurs d’expression innovants en vaccinologie, un ARN messager ou un adénovirus recombinant. Cependant, la maîtrise de l’épidémie nécessite une campagne de vaccination de masse bien organisée. Elle requiert aussi la surveillance attentive de nombreux paramètres tels que la survenue d’événements indésirables, la durée de l’immunité induite, l’efficacité vaccinale contre les variants émergents du SARS-CoV-2, l’intérêt ou non de vacciner les personnes déjà infectées, la vaccination des patients immunodéprimés. La vaccination doit s’accompagner du maintien des mesures et gestes barrières et d’une amplification des investigations clinico-biologiques tant pour valider son efficacité sur l’épidémie de Covid-19 que pour préparer les développements futurs en vaccinologie. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Outside of SARS-CoV-2 vaccines, there is little positive outlook for the control of Covid-19 epidemic. Schematically, two antagonistic and extreme strategies have been proposed, zero-covid and herd immunity. Between the two, often oscillating measures, based on medical but also societal and political considerations, have been taken without any major effect on the course of the epidemic. Vaccines are a game-changer by providing a real opportunity to sustainably protect everyone against infection and eliminate the circulation of the virus. The Pfizer, Moderna and AstraZeneca vaccines, the three currently authorized in France, overall induce remarkable protection rates of 95 %, 94 % and 70 % respectively. The surprise came from that this efficacy was obtained after a rapid development, by targeting only the viral protein S as antigen, and by using the administration of expression vectors innovative in vaccinology, consisting of either messenger RNA or recombinant adenovirus. However, bringing the epidemic under control requires a well-organized mass vaccination campaign. It also requires careful monitoring of many parameters such as the occurrence of adverse events, duration of induced immunity, vaccine efficacy against emerging variants of SARS-CoV-2, interest or not of vaccinating people already infected, vaccination of immunocompromised patients. Vaccination must be accompanied by the maintenance of barrier measures and gestures and an amplification of clinical and biological investigations both to validate its effectiveness on the Covid-19 epidemic and to prepare for future developments in vaccinology. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | vaccin adénovirus recombinant |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | variant du SARS-CoV-2 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Covid-19 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | vaccin à ARN messager |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | mRNA vaccine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Covid-19 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | recombinant adenovirus vaccine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | SARS-CoV-2 variant |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Virologie | 25 | 3 | 2021-05-01 | p. 141-147 | 1267-8694 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-virologie-2021-3-page-141?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-virologie-2021-3-page-141?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux